Denosumab update

Current Opinion in Rheumatology

Volumn 21, Issue 4, 2009, Pages 369-373

  Lewiecki, E Michael ^a  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

Author keywords

Fracture; Osteoporosis; RANKL; Rheumatoid arthritis; Treatment

Indexed keywords

ALENDRONIC ACID; CALCIUM; DENOSUMAB; METHOTREXATE; PLACEBO; VITAMIN D;

BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; DIVERTICULITIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; HUMAN; LABYRINTHITIS; NEOPLASM; PNEUMONIA; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ALENDRONATE; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DISEASE PROGRESSION; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RANK LIGAND;

EID: 67149091085     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32832ca41c     Document Type: Review

References (26)

1. Klibanski A, Adams-Campbell L, Bassford T, et al. Osteoporosis prevention, diagnosis, and therapy. J Am Med Assoc 2001; 285:785-795. (Pubitemid 32167238)
2. US Department of Health and Human Services. Bone Health and osteoporosis: a report of the surgeon general. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004.
3. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22:465-475.
4. Walsh NC, Crotti TN, Goldring SR, et al. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005; 208:228-251.
5. Kavanaugh A. Economic consequences of established rheumatoid arthritis and its treatment. Best Pract Res Clin Rheumatol 2007; 21:929-942. (Pubitemid 47377807)
6. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19:1059-1066. (Pubitemid 41110556)
7. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004; 95:1046-1057. (Pubitemid 39557891)
8. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
9. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. J Am Med Assoc 2004; 292:490-495. (Pubitemid 38988958)
10. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005; 5:618-625. (Pubitemid 41614462)
11. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354:821-831. (Pubitemid 43290920)
12. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res 2007; 22:1832-1841.
13. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008; 43:222-229. The effects of denosumab continuation, discontinuation, and restarting suggest that BMD and BTM effects are favorable with continuation, reversible with discontinuation, and recoverable with restarting.
14. Cohen SB, Lewiecki EM, Liu Y, et al. Phase 2 study of denosumab (AMG 162) in postmenopausal women: subanalyses and supplemental safety. J Bone Miner Res 2005; 20 (Suppl 1):S295.
15. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008; 93:2149-2157. DEFEND is the pivotal trial for denosumab registration for the prevention of PMO. (Pubitemid 351831529)
16. Cummings SR, McClung MR, Christiansen C, et al. A phase III study of the effects of denosumab on vertebral, nonvertebral, and hip fracture in women with osteoporosis: results from the FREEDOM trial. J Bone Miner Res 2008; 23 (Suppl 1):S80. FREEDOM is the phase III registration trial for the treatment of PMO, showing reduction in the risk of vertebral, hip, and nonvertebral fracture risk.
17. Amgen Inc. Form 8-K. http://investors.amgen.com/phoenix.zhtml?c= 61656&p=irol-sec. Accessed on 16 September 2008.
18. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009; 24:153-161. DECIDE showed that denosumab increases BMD and suppresses BTMs more than alendronate, with a similar safety profile.
19. Kendler DL, Benhamou CL, Brown JP, et al. Effects of denosumab vs. alendronate on bone mineral density (BMD), bone turnover markers (BTM), and safety in women previously treated with alendronate. J Bone Miner Res 2008; 23 (Suppl 1):S473. STAND demonstrated that patients switched from alendronate to denosumab have a greater BMD increase than those continuing to take alendronate.
20. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58:1299-1309. Denosumab was shown to have favorable effect on bone erosion scores in patients with RA who are also taking methotrexate.
21. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93:2645-2668.
22. Tang L, Persky AM, Hochhaus G, et al. Pharmacokinetic aspects of biotechnology products. J Pharm Sci 2004; 93:2184-2204. (Pubitemid 39129617)
23. Peterson MC, Stouch BJ, Martin SW, et al. The pharmacokinetics of denosumab (AMG 162) following various multiple subcutaneous dosing regimens in postmenopausal women with low bone mass. J Bone Miner Res 2005; 20:S293.
24. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-324.
25. McQueen F, Lassere M, Edmonds J, et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies. Summary of OMERACT 6 MR imaging module. J Rheumatol 2003; 30:1387-1392. (Pubitemid 36666374)
26. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000; 27:261-263. (Pubitemid 30058662)